On Friday, 24 May 2019, Knowledge Ecology International (KEI) will convene an expert panel, “Assessing the implications of developments in cell and gene-based therapies (including CAR T and CRISPR): What role should WHO should play?” from 12h30 to 14h30 in… Continue Reading
In an order dated April 11, 2019, Judge Peter J. Messitte granted the NIH’s motion to dismiss for lack of jurisdiction in the lawsuit filed by KEI, which appealed an NIH decision to grant an exclusive license on a CAR… Continue Reading
The following are comments by KEI, UACT, Social Security Works, HealthGap, Public Citizen, Dr. Ophira Ginsbug and James Love on an NIH proposed exclusive license for patents on a CAR T technology for “Treatment of FMS-Like Tyrosine Kinase 3 (FLT3)… Continue Reading
In a recent Federal Register notice, the National Institutes of Health (NIH) has announced its intent to grant an exclusive patent license on chimeric antigen receptor (CAR) therapies for the treatment of certain cancers to ElevateBio, a company located in… Continue Reading
On Monday, October 15, 2018, Judge Peter J. Messitte of the United States District Court, District of Maryland, convened a hearing on a motion by the NIH to dismiss a lawsuit (Case 8:18-cv-01130-PJM) by KEI regarding the decision by the… Continue Reading
Attached are comments from 8 health and fair groups regarding a prospective grant of an exclusive license to NIH owned patent, for the development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the treatment of human Cancer, to Atara Biotherapeutics… Continue Reading
Update: the NIH has rejected our request for expedited processing of the FOIA, on the grounds that KEI did not demonstrate “that there exists an urgency to inform the public” about the costs of the NIH CAR T or mesothelin… Continue Reading
The NIH has filed a motion to dismiss in our lawsuit over the NIH license of CAR T patents to Gilead. See original KEI complaint here: https://www.keionline.org/27669. As expected, the NIH is challenging KEI’s standing. KEI has 15 days to… Continue Reading
On April 19, 2018, KEI filed a lawsuit against the National Institutes of Health (NIH) to block or invalidate an exclusive license of patents on a new chimeric antigen receptor T-cell (CAR T) therapy to Gilead Sciences. A copy of… Continue Reading